The article provides a comprehensive analysis of the multiple myeloma pipeline, highlighting clinical trials, drug development, and therapeutic advancements by key pharmaceutical companies. It details recent trial results, emerging therapies, and pipeline insights from over 75 companies, including Sanofi, Johnson & Johnson, and Carsgen Therapeutics.

The article discusses recent advancements in multiple myeloma (MM) clinical trials, including Phase III results from Sanofi, Johnson & Johnson, and Bristol Myers Squibb, as well as emerging therapies and pipeline analysis involving over 75 companies. Key developments include new drug approvals, trial results, and pipeline therapies for MM treatment.

The report highlights 75+ pharmaceutical companies and 80+ pipeline therapies for multiple myeloma, including clinical trials and drug developments by companies like Celgene, Bristol-Myers Squibb, Novartis, and GlaxoSmithKline. Key therapies include CAR-T cell therapies, monoclonal antibodies, and novel agents targeting BCMA, CD38, and other receptors.

CASI Pharmaceuticals held a special conference call to update stakeholders on its business and clinical progress, with Dr. Wei-Wu He, the company's Chairman and CEO, participating.

DelveInsight's 2025 report highlights a robust Multiple Myeloma pipeline with 75+ companies and 80+ pipeline therapies. The report details clinical trials, drug development stages, and emerging therapies for relapsed/refractory multiple myeloma, including studies by Kite, GlaxoSmithKline, AbbVie, Bristol-Myers Squibb, and Janssen Research & Development LLC.